Health Assessment, Patient treatment satisfaction and Quality-of-Life in insulin-naive type 2 diabetes Patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents. A multicenter, prospective, crossover, open randomized clinical phase-IV trial Investigate the impact of insulin glargine vs. NPH basal insulin on a composite diabetes related quality of life score (DRQoL), consisting of a standardized and unweighted Insulin Treatment Experience...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and safety of intra-articular multiple doses of 500 mg icatibant including 40 mg triamcinolone as calibrator in a randomized, double-blind, parallel-group, placebo-controlled 13-week multi-centre study in patients with symptomatic knee osteoarthritis *After the clinical start of the study, an extension of the follow-up period has been established by Amendment n° 2, extending the observation period by further 26 weeks; thus, the overall study duration will become totally 39 weeks The primary objective of the study is to compare the overall treatment effect of pain relief in the affected knee joint between icatibant and placebo in terms of daily average of general knee pain Vis...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional insulin regimen in type 2 diabetes mellitus patients with poor glycemic control pretreated with a two-injection conventional insulin therapy The primary study objective is to demonstrate superior efficacy of an intensified insulin regimen with insuline glulisine and insulin glargine to a two-injection conventional insulin regimen in terms ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Pharmacokinetics, pharmacodynamics and safety of intra-articular multiple doses of 500 mcg icatibant in an uncontrolled 13-week multi-center study in patients with symptomatic knee osteoarthritis To assess the systemic exposure of icatibant after intra-articular injection

• Pays Aucun
• Organes Aucun
• Spécialités Aucune